Dirk Arnold, MD, PhD, Asklepios Tumorzentrum Hamburg, Hamburg, Germany, discusses the expanding role of liquid biopsies in improving outcomes and patient care in gastrointestinal (GI) oncology. Liquid biopsies can sensitively characterize tumors more efficiently, and the genetic profile of tumors can additionally be assessed over a long period of time. Detecting molecular changes will enable clinicals to alter the course of treatment to the patient’s needs. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть